OTCM
XVIPF
Market cap730mUSD
Oct 02, Last price
21.80
Name
Xvivo Perfusion AB
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Xvivo Perfusion AB (publ), a medical technology enterprise based in Gothenburg, Sweden, specializes in developing cutting-edge solutions for the preservation and perfusion of organs, tissues, and cells, crucial for transplantation. The company's reach spans diverse global markets, including Sweden, the United States, broader North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its extensive product lineup features the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system engineered for secure normothermic ex vivo lung perfusion (EVLP). This is supported by the XPS Disposable Lung Kit, which supplies all necessary sterile consumables. Xvivo Perfusion also provides STEEN Solution, a uniquely formulated buffered extracellular solution for perfusing isolated donor lungs during EVLP procedures. Further offerings include Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution; the XVIVO Silicone Tubing Set for rapid flushing of donor lungs during the procurement phase; and both the XVIVO LS and XVIVO Disposable Lung Set, specialized devices for EVLP. Additionally, the company offers the XVIVO Organ Chamber, a single-use sterile container designed for the temporary holding of isolated lungs before transplantation into a recipient, alongside the XVIVO Lung Cannula Set, another sterile, single-use disposable product. The company was founded in 1998.
Key people
Chairman of the Board · since 2018
Christoffer Rosenblad
Chief Executive Officer · since 2022
Lena Hagman
Deputy Chief Executive Officer, Chief Operating Officer · since 2024
Kristoffer Nordstroem
Chief Financial Officer · since 2022
Johan Holmstroem
Senior Vice President, Commercial Europe & RoW · since 2024
Mark Reade
Senior Vice President, North America
Jaya Tiwari
Senior Vice President, Clinical & Regulatory Affairs, North America · since 2024
Ylva Vihoj
Senior Vice President of Human Resources · since 2024
Andreas Wallinder
Chief Medical Officer
Goeran Dellgren
Independent Director · since 2022
Lars Henriksson
Independent Director · since 2020
Lena Hoeglund
Independent Director · since 2020
Camilla Oberg
Independent Director · since 2016
Independent Director · since 2023
Legal address
Gemenskapens Gata 9
Mölndal 431 53
SE
Mölndal 431 53
SE
Headquarters
Box 53015
GÖTEBORG 400 14
SE
GÖTEBORG 400 14
SE
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||